Immunodiagnostic Systems Hldgs PLC Launch of automated IDS Cortisol assay (1267V)

TIDMIDH

RNS Number : 1267V

Immunodiagnostic Systems Hldgs PLC

04 August 2020

Immunodiagnostic Systems Holdings plc.

4 August 2020

Launch of automated IDS Cortisol assay - new addition to the IDS Hypertension portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, today launched the IDS Cortisol assay for use with the IDS Automated System in the European market and other countries which accept the CE mark.

Measurement of Cortisol concentrations can be used to assist in the diagnosis and treatment of disorders of the adrenal gland, such as hypo- and hyper-cortisolism, most commonly referred to as Addison's disease and Cushing's syndrome. Many common signs of Cushing's such as obesity, high blood pressure and increased blood glucose are frequently observed in today's society. This new assay complements the existing Aldosterone, Direct Renin, ACTH and Salivary Cortisol assays in the IDS Hypertension panel, improving laboratory workflow with the IDS Automated System.

The Global market size of Cortisol testing is estimated to be approximately GBP8.7 million worldwide.

For further information:

   Immunodiagnostic Systems Holdings plc                   Tel: [phone] 

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: [phone]

James Steel

Oliver Jackson

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

PRLUPUQGRUPUGAC

(END) Dow Jones Newswires

August 04, 2020 11:18 ET (15:18 GMT)